An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Just weeks after being acquired by Allergan, the team behind Chicago-based Naurex is launching a new startup: Aptinyx. It'll focus on developing drugs for diseases of the brain and nervous system.